From insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals.
This review examines pharmacological strategies relevant to T2DM prevention in individuals without established diabetes who have prediabetes and/or obesity associated with a high risk of progression to T2DM, with particular emphasis on incretin-based obesity pharmacotherapy.